Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.47 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | NPY1R | P25929 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPY2R | P49146 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18048070 | 1.00 | PRMT6 (0.48) | PRMT6ADORA1P2RY12ADORA3ADORA2A | |
| SCHEMBL20353074 | 1.00 | PRMT6 (0.48) | PRMT6ADORA1P2RY12ADORA3ADORA2A | |
| SCHEMBL20248698 | 1.00 | PRMT6 (0.48) | PRMT6ADORA1P2RY12ADORA3ADORA2A | |
| SCHEMBL29558159 | 1.00 | PRMT6 (0.48) | PRMT6ADORA1P2RY12ADORA3ADORA2A | |
| SCHEMBL18992232 | 1.00 | PRMT6 (0.48) | PRMT6ADORA1P2RY12ADORA3ADORA2A | |
| SCHEMBL17860554 | 0.97 | PRMT6 (0.48) | PRMT6ADORA1P2RY12ADORA3ADORA2A | |
| SCHEMBL18496436 | 0.97 | PRMT6 (0.48) | PRMT6ADORA1P2RY12ADORA3ADORA2A | |
| SCHEMBL20483101 | 0.96 | PRMT6 (0.46) | PRMT6ADORA1P2RY12ADORA3ADORA2A | |
| SCHEMBL29814296 | 0.96 | PRMT6 (0.46) | PRMT6ADORA1P2RY12ADORA3ADORA2A | |
| SCHEMBL20248696 | 0.95 | PRMT6 (0.47) | PRMT6ADORA1P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667664-B2 | Cyclic dinucleotides for cytokine induction | KAYLA THERAPEUTICS (FR) | 2023-06-06 | — | — | US | disclosed |
| US-10011630-B2 | Cyclic dinucleotides for cytokine induction | INVIVOGEN (FR) | 2018-07-03 | — | — | US | disclosed |
| US-20160362441-A1 | CYCLIC DINUCLEOTIDES FOR CYTOKINE INDUCTION | KAYLA THERAPEUTICS (FR) | 2016-12-15 | — | — | US | disclosed |
| US-20160362441-A1 | CYCLIC DINUCLEOTIDES FOR CYTOKINE INDUCTION | KAYLA THERAPEUTICS (FR) | 2016-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362441-A1 | CYCLIC DINUCLEOTIDES FOR CYTOKINE INDUCTION | IL1B, IFNG, IFNAR1 | PRMT6 1821/4885ADORA1 300/4885P2RY12 908/4885 |
| US-10011630-B2 | Cyclic dinucleotides for cytokine induction | IL1B, IFNG, IFNAR1 | PRMT6 1821/4885ADORA1 300/4885P2RY12 908/4885 |
| US-11667664-B2 | Cyclic dinucleotides for cytokine induction | IL1B, IFNG, IFNAR1 | PRMT6 1821/4885ADORA1 300/4885P2RY12 908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.